MRD Everywhere: Measurable Residual Disease Is a Recurring ASH 2026 Theme

More than a hundred abstract titles reference MRD. A sampling of the oral presentations:

• AML: Abstract 61 (venetoclax + “7+3” in NPM1-mutated AML; Kamel; NCT05342584), Abstract 65 (VERDI, preemptive venetoclax + azacitidine for MRD persistence or relapse; Esteve; NCT06668558), Abstract 299 (tumor-agnostic plasma cfDNA methylation profiling for MRD; Gui; NCT05224661), Abstract 385 (tumor-informed NGS for MRD monitoring, substudy of the QUIWI trial; Diaz).
• Myeloma: Abstract 111 (PERSEUS long-term analysis, MRD-guided daratumumab maintenance discontinuation; Sonneveld), Abstract 115 (anitocabtagene autoleucel in newly diagnosed myeloma, GEM-ANITOFIRST).
• CLL: Abstract 255 (MRD-guided stop-and-restart, HOVON141/VISION; Kater).

Sessions 619 (AML: Disease Burden and Measurable Residual Disease) and 803 (Emerging Tools, Techniques, and AI in Hematology) are worth a look for anyone building MRD into trial endpoints.